logo
logo

Egret Therapeutics Completes Oversubscribed Pre-A Financing Round

Egret Therapeutics Completes Oversubscribed Pre-A Financing Round

02/15/22, 11:09 AM
Egret Therapeutics, a clinical-stage biotherapeutics company focused on the treatment of neurological diseases, announced today the completion of its pre-A financing. The funding was led by FAScinate Therapeutics, Inc, a clinical neurological diseases company, with participation from Turret Capital Management and private investors.

Company Info

Company
Egret Therapeutics
Additional Info
Egret Therapeutics is a clinical-stage biotherapeutics company. The company is focused on developing products to address areas of clinical unmet need in neurological diseases. For more information, visit us at www.egrettherapeutics.com.